| Atosiban group | Placebo group | P-value | Relative risk (95% CI) |
---|---|---|---|---|
Positive pregnancy test rate | 52.6% (51/97) | 44.3% (43/97) | 0.250 | 1.186(0.885–1.589) |
Clinical pregnancy rate | 50.5% (49/97) | 42.3% (41/97) | 0.249 | 1.195(0.881–1.621) |
Ongoing pregnancy rate | 42.3% (41/97) | 35.1% (34/97) | 0.302 | 1.206(0.844–1.723) |
Live birth rate | 42.3% (41/97) | 35.1% (34/97) | 0.302 | 1.206(0.844–1.723) |
Miscarriage rate | 15.7% (8/51) | 16.3% (7/43) | 0.938 | 0.964(0.380–2.441) |
Multiple pregnancy rate | 21.6% (11/51) | 18.6% (8/43) | 0.721 | 1.159(0.513–2.620) |
Implantation rate | 34.4% (63/183) | 29.0% (53/183) | 0.261 | 1.189(0.878–1.608) |
Ectopic pregnancy rate | 2% (1/51) | 2.3% (1/43) | 1 | 0.834(0.054–13.083) |
Congenital abnormality rate | 0 | 0 | Â | Â |